← Back to Search

Compass Course for Breast Cancer Survivors (CC-V Trial)

N/A
Waitlist Available
Led By Mary V Radomski, OTR/L, PhD
Research Sponsored by Mary Radomski
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (about 4 months)
Awards & highlights

CC-V Trial Summary

This trial will test whether the Compass Course, a group intervention for individuals with breast cancer, is feasible and efficacious when delivered over Zoom.

Eligible Conditions
  • Breast Cancer

CC-V Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (about 4 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (about 4 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Engagement in Meaningful Activities survey
Change in Meaning in Life Questionnaire
Change in Purpose Status Question
+1 more
Secondary outcome measures
Change in Beck Depression Inventory -- II
Change in State-Trait Anxiety Inventory

CC-V Trial Design

1Treatment groups
Experimental Treatment
Group I: Compass CourseExperimental Treatment1 Intervention
Virtual Compass Course

Find a Location

Who is running the clinical trial?

Mary RadomskiLead Sponsor
2 Previous Clinical Trials
348 Total Patients Enrolled
1 Trials studying Breast Cancer
300 Patients Enrolled for Breast Cancer
Mary V Radomski, OTR/L, PhDPrincipal InvestigatorSenior Scientific Advisor
1 Previous Clinical Trials
48 Total Patients Enrolled

Media Library

Compass Course Clinical Trial Eligibility Overview. Trial Name: NCT04767464 — N/A
Breast Cancer Research Study Groups: Compass Course
Breast Cancer Clinical Trial 2023: Compass Course Highlights & Side Effects. Trial Name: NCT04767464 — N/A
Compass Course 2023 Treatment Timeline for Medical Study. Trial Name: NCT04767464 — N/A
~5 spots leftby May 2025